Synaptic roles of cyclin-dependent kinase 5 & its implications in epilepsy

Aparna Banerjee Dixit¹, Jyotirmoy Banerjee¹, Manjari Tripathi², Chitra Sarkar³ & P. Sarat Chandra⁴

¹Center for Excellence in Epilepsy, A Joint National Brain Research Centre (NBRC)- All India Institute of Medical Sciences (AIIMS) Collaboration, NBRC, Gurugram & Departments of ²Neurology, ³Pathology & ⁴Neurosurgery, AIIMS, New Delhi, India

Received February 28, 2017

There is an urgent need to understand the molecular mechanisms underlying epilepsy to find novel prognostic/diagnostic biomarkers to prevent epilepsy patients at risk. Cyclin-dependent kinase 5 (CDK5) is involved in multiple neuronal functions and plays a crucial role in maintaining homeostatic synaptic plasticity by regulating intracellular signalling cascades at synapses. CDK5 deregulation is shown to be associated with various neurodegenerative diseases such as Alzheimer’s disease. The association between chronic loss of CDK5 and seizures has been reported in animal models of epilepsy. Genetic expression of CDK5 at transcriptome level has been shown to be abnormal in intractable epilepsy. In this review various possible mechanisms by which deregulated CDK5 may alter synaptic transmission and possibly lead to epileptogenesis have been discussed. Further, CDK5 has been proposed as a potential biomarker as well as a pharmacological target for developing treatments for epilepsy.

Key words Cyclin-dependent kinase 5 - epilepsy - epileptogenesis - neurodegenerative diseases - pharmacoresistant - seizures - synaptic plasticity

Introduction

Imbalance between excitation and inhibition is a hallmark of epileptogenesis. Although numerous studies have reported association between abnormal synaptic transmission and epileptogenesis, yet the molecular mechanisms underlying genesis of seizures in patients with epilepsy, especially with drug-resistant epilepsy (DRE), is still unclear. It is estimated that in about 30-40 per cent of epilepsy patients, treatment with antiepileptic drug (AED) alone will not result in complete seizure control¹ (Fig. 1). Most patients with DRE can be diagnosed early in their presentation after they failed treatment with two AEDs². DRE patients have an increased risk of mortality and a poor social life. They undergo various investigations such as video electroencephalography (EEG) to confirm the diagnosis of epilepsy and magnetic resonance imaging (MRI) study to identify a potential surgical lesion. Functional imaging techniques such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) localize cerebral dysfunction by identifying disturbances in an individual’s metabolism or blood flow. A recently emerged non-invasive technique,
magnetoencephalography (MEG), is very potent in localizing the irritative zone in lesional and non-lesional epilepsy surgery patients as well as in functional mapping of eloquent (sensory, motor and language) cortex for surgical planning. Other options are suggested for patients who are either not suitable candidates for surgery or those who continue to have seizures even after surgery. These include treatment trials with other AEDs appropriate for their epilepsy syndrome and/or vagus nerve stimulation (VNS) or responsive cortical stimulations or ketogenic diets. With these treatments, the chances of seizure remission are not high, but certainly, the reductions in seizure frequency and improvement in the quality of life are possible in most of the patients. Patients with localization-related DRE undergo resective surgical therapy and have greater chances of achieving surgical freedom as compared to those receiving medical treatment for DRE. Intraoperative co-registration of MRI, PET, and electrocorticography (ECoG) provides better objective localization of the epileptogenic foci. ECoG provides useful information for the prediction of surgical success in surgically remediable epilepsy. Despite using combination of all available invasive and non-invasive modalities, the epileptogenic zone cannot be fully defined, and in more than 30 per cent of cases, the patients are not benefited, mostly due to inability to precisely localize the epileptogenic foci. Thus, the challenge is to understand the molecular mechanisms of epileptogenesis, which will aid in identifying potential diagnostic biomarkers as well as novel therapeutic targets of epilepsy. The tissues resected during epilepsy surgery are the ideal model systems for studying the process of epileptogenesis, and only a complementary and multi-disciplinary approach will lead to a novel biomarker.

To understand the molecular basis of DRE, whole-genome transcriptomic analysis approach has been used to identify genes involved in the pathophysiology of DRE. Several potential candidate genes, mostly linked to, inflammation and innate immunity, synaptic transmission and network modulation, were found to be modulated. Various kinases involved in phosphorylation of microtubule-associated proteins (MAPs) including glycogen synthase kinase-3 beta (GSK3β), cyclin-dependent kinase 5 (CDK5) MAP kinase family members (ERK, P38) and casein kinase 2 (alpha 1 polypeptide) were abnormally expressed. MAP kinase, CDK5 and casein kinase 2 were shown to be deregulated in both DRE patients and animal models of epilepsy.

Deregulation of the mechanisms inhibiting excitatory synaptic transmission or promoting the mechanisms that facilitate excitation can lead to epileptogenesis. Seizure-induced alterations of synaptic plasticity including neuronal sprouting, reorganization of synapase, neurogenesis and gliosis can result in the development of abnormal neural network. This will lead to a loss of the inhibitory effect of endogenous antiepileptic system. These changes will further prevent the traditional AEDs from reaching their targets and gradually leading to the development of DRE. Many studies have shown that neuropeptides such as somatostatin (SST), neuropeptide Y (NPY), galanin and nociceptin/orphanin FQ (N/OFQ) have antiepileptic activity and thus act as endogenous antiepileptic agents. Due to high-frequency stimulation (as observed in seizure), interneuronal peptides are released from interneurons causing inhibition of synaptic transmission. In addition, adenosinergic system is reported to have an endogenous antiepileptic function by virtue of its anticonvulsant action. It is important to understand the processes through which the neuronal activities are synchronized which in turn lead to generation of seizures. Modulation of synaptic plasticity will lead to modulation of neurotransmission which is crucial for memory formation as well as higher cognition in the central nervous system (CNS). Various kinases including a serine/threonine kinase CDK5 regulate...
synaptic plasticity by modulating synaptic composition of postsynaptic density (PSD) by phosphorylation of various synaptic proteins. However, the regulation of neural plasticity by CDK5 is still not clearly understood. Studies with transgenic animals have associated CDK5 with an increasing number of higher brain functions and neurodegenerative diseases such as drug addiction, spatial learning, memory formation and Alzheimer’s disease. Mirza et al. published an integrated analysis of several array-based studies on the transcriptional profiling of human epilepsy where they have identified CDK5 signalling pathway as one of the top canonical pathways modulated in epilepsy strongly supporting the role of CDK5-mediated signalling in epilepsy. This review is mainly focussed on the role of CDK5 in synaptic transmission and suggests that altered CDK5 functions in epilepsy patients may affect the synaptic transmission, thereby contributing to the process of epileptogenesis.

Role of cyclin-dependent kinase 5 (CDK5) in neuronal function

CDK5 is a unique multi-functional proline-directed serine/threonine kinase which is activated by two non-cyclin activators, p35 and p39. CDK5 shares 60 per cent homology to cell division cycle protein 2. Initially, CDK5 was shown to have no role in the cell cycle, but recently, it has been shown to regulate several cell cycle proteins. Most of these phosphorylate retinoblastoma proteins which play a crucial role in cell cycle exit. CDK5/p35 complex bound to the membrane is inactive, whereas the unbound complex in the cytoplasm is the active form. CDK5 localizes both in the cytoplasm and nucleus. Myristoylated p35 or p39 leads to the recruitment of CDK5 to cellular membranes in the cell soma and the dendrites. Cleavage of p35 into p25 affects the activity, localization and interaction network of CDK5. Maximal enzymatic activity of CDK5 and its activators is found in the postmitotic neurons in the CNS. CDK5-null mutants indicated precise modulations in the cerebral cortex, cerebellum and hippocampal regions. It is implicated in multiple neuronal functions, including neuronal survival and migration, neurite outgrowth, synaptic vesicle cycle, synaptic transmission and plasticity (Fig. 2). Furthermore, CDK5 along with its cofactors has been shown to regulate neuronal excitability. Large numbers of synaptic proteins have been reported as CDK5 substrates. CDK5 inhibition has been shown to unmask the silent synapses by potentiating the release of neurotransmitters in neurons.

CDK5 is linked to the neuronal death in Alzheimer’s and Parkinson’s disease and plays an important role in the pathophysiology of these neurodegenerative diseases. Understanding of the precise role of CDK5 modulation of neurotransmission affecting synaptic dysfunction associated with these neurological disorders may open new avenues for novel therapeutics.

Role of cyclin-dependent kinase 5 (CDK5) in abnormal synaptic transmission associated with epilepsy

CDK5 function in synaptic vesicle cycle

Numerous studies have identified defects in the synaptic vesicle cycle as one of the reasons for the abnormal release. CDK5 phosphorylates various proteins that regulate synaptic vesicle cycle. The list of some of the proteins includes: Amphiphysin, Dynamin, Munc18, Plectrin, Septin, Synapsin, Synaptojanin, CASK, Cav2.1, Cav2.2, DARPP-32, L-catenin, Kalinin, NR2A, PP-1, P2-P inhibitor, PSD 95, SPAR, Tpm.

Fig. 2. Major identified cyclin-dependent kinase 5 (CDK5) substrates. Substrates are categorized based on their functions. Superscript numerals denote reference numbers.

DISC1, disrupted in schizophrenia 1 protein; FAK2, flagellar adenylate kinase; NUDEL, nuclear distribution protein nude-I; P27, cyclin-dependent kinase inhibitor 1B; CRMp2, dihydroxyphosphatidylcholine like 2; c-Src, proto-oncogene tyrosine-protein kinase; MAP1B, microtubule-associated protein 1B; P39, cyclin-dependent kinase 5, regulatory subunit 2; PAK1,  serine/threonine-protein kinase; RasGRF2, ras-specific guanine nucleotide-releasing factor 2; TrkB, BDNF/NT-3 growth factors receptor; CASK, peripheral plasma membrane protein; CaV1.2, voltage-dependent L-type calcium channel subunit alpha; CaV2.1, voltage-gated calcium channel alpha 1A subunit; DARPP-32, dopamine- and cAMP-regulated neuronal phosphoprotein; NR2A, glutamate receptor, ionotropic, N-methyl D-aspartate; PP-1, protein phosphatase 1; PSD95, postsynaptic density protein 95; SPAR, surfactant protein A binding protein; TH, tyrosine 3-monooxygenase; APP, amyloid beta A4 protein; MEF2D, myocyte-specific enhancer factor 2D; NF, neurofibromin; Prx2, peroxidase; Tau, Microtubule-associated protein tau; Ape1, DNA-(apurinic or apyrimidinic site) lyase; ATM, serine-protein kinase ATM; Bel-2, apoptosis regulator Bel-2; Cdh1, cadherin-1; ErbB3, receptor tyrosine-protein kinase erbB-3; GR, glucocorticoid receptor; JNK3, mitogen-activated protein kinase 10; MEK1, dual specificity mitogen-activated protein kinase 1; mSds3, component of the functional mSin3/HDAC corepressor complex; p35, cyclin dependent kinase 5 regulatory subunit 1; PIPK1-γ, phosphatidylinositol-4-phosphate 5-kinase type 1 gamma; PPAR-γ, peroxisome proliferator-activated receptor gamma.
substrates such as synapsin I, Munc18, Sept5, calcium/calmodulin-dependent serine protein kinase 3, P/Q subtype voltage-dependent calcium channel and Petaire1, a CDK-related kinase, and plays an important role in synaptic vesicle cycle. CDK5 regulates clathrin-mediated endocytosis by phosphorylating various substrates including amphiphysin I, dynamin I, phosphatidylinositol-4-phosphate 5-kinase type I gamma (PIPKIγ) and synaptotagmin 1, a Pl(4,5)P2 phosphatase. There is evidence showing implication of CDK5 in the inhibition of dopamine (DA) release in the striatum. Collectively, CDK5 has been proposed to inhibit the neurotransmitter release. Deregulation of CDK5 may result in excessive release of neurotransmitter leading to epileptogenesis.

Modulation of neurotransmitter receptors at glutamatergic synapses

There are reports showing alterations in the excitatory (glutamatergic) and inhibitory (GABAergic) synaptic transmission in resected surgery zone from epilepsy patients. Involvement of CDK5 in modulating glutamatergic neurotransmission has been reported. Putkonen et al. reported kainic acid (KA) induced activation of CDK5 in cultured hippocampal neurons as well as in vivo in the hippocampus. Glur6/7 and PSD95 were found to be decreased after KA treatment in the hippocampal neurons. Further, CDK5 inhibition using roscovitine, silencing RNA or dominant-negative CDK5 constructs was able to counteract the decreases in the levels of these proteins in cultured hippocampal neurons. This study provided crucial information on the role of CDK5 in modulating synaptic plasticity and excitotoxicity after KA treatment. CDK5 has been shown to influence the clustering of the PSD95 complexes and regulate trafficking of metabotropic GluRs and N-methyl-d-aspartate receptor (NMDAR) subunits. CDK5 enhances NMDA-mediated currents in hippocampal neurons by phosphorylating the NMDAR subunit 2A (NR2A). CDK5 also facilitates calpain-mediated degradation of the NR2B subunit of NMDAR. A study by Putkonen et al. reported the role of CDK5 in regulating the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor (AMPAR) subunit GluR2-mediated synaptic activity by phosphorylating D-catenin. CDK5 primes polo-like kinase 2 (Plk2) which in turn affects the recruitment and degradation of RapGAP (Spine Associated RapGAP) that interacts with PSD95 and needed to maintain homeostasis during increased excitotoxicity by negative regulation of the synaptic activity. CDK5 knockout (KO) may affect calpain-mediated p25 generation, leading to disruption of the normal homeostatic mechanisms preventing seizures. CDK5 also regulates acetylcholine receptor (AChR) clustering and plays a role in the neuromuscular junction (NMJ) development. NMJ phenotype of CDK5-KO mice demonstrated that the bandwidth of AChR endplate was enlarged in CDK5/2 diaphragm.

CDK5 also modulates expression of neurotransmitter receptors at the synapse. CDK5 upregulates GABA receptor transcription in the CNS neurons by phosphorylating the transcription factor signal transducer and activator of transcription 3 (STAT3). CDK5-mediated regulation of myocyte-enhancing factor 2 (MEF2) is linked with neuronal death and also in the death of dopaminergic neurons in animal model of Parkinson’s disease. Activity-dependent regulation of MEF2 activity also appears to affect the number of excitatory synapses. Thus, deregulation of CDK5 affecting neurotransmitter receptor transcription at the synapse may be another possible mechanism leading to epileptogenesis.

Dopaminergic signalling

DA-mediated modulation of intracellular signalling pathways has been shown to be involved in long-term epileptogenesis. CDK5-mediated phosphorylation of the DA synthesis catalytic enzyme, tyrosine hydroxylase, regulates its stability in the presynaptic terminals. In postsynaptic neurons, CDK5 regulates cyclic-AMP-regulated phosphoprotein-32kd [dopamine- and cyclic-AMP regulated phosphoprotein-32kd (DARPP-32)] which is a crucial molecule in DA signalling. CDK5 antagonizes dopamine 1 receptor (D1R)-mediated protein kinase A (PKA) signalling by phosphorylating T75 residue of DARPP-32 and turning it into a PKA inhibitor and protein phosphatase 1 (PP1) activator. In contrast, phosphorylation of DARPP-32 at T34 residue through D1R-PKA signalling inhibits PP1 which in turn promotes phosphorylation activity. Collectively, CDK5 plays an important role in maintaining dopaminergic homeostasis. Various studies report crosstalk between the CDK5- and GSK3β-mediated signalling pathways. CDK5 inhibits GSK3β by either inhibiting phosphatases or activating protein kinase B (PKB) or Akt through erythroblastosis oncogene B (ErbB) signalling (Fig. 3). Modulation of Akt/GSK3 signalling by DA receptors has been shown to influence NMDA receptor-mediated synaptic plasticity. CDK5 has been shown to down-regulate D2R surface expression,
Deregulation of these pathways by CDK5 may alter synaptic signaling might further regulate CDK5 expression via ΔFosB.

Fig. 3. Hypothesized model of the pathways/substrates regulated by cyclin-dependent kinase 5 (CDK5) in dopamine and glutamate signalling. Depicted are postsynaptic dopamine/PKA/Thr34-DARPP-32, glutamate/CDK5/Thr75-DARPP-32, CDK5/PI3K/AKT, ΔFOSB/CDK5 signalling cascades. CDK5 might play important role in regulating synaptic transmission by either directly influencing glutamate signaling through NMDA/AMPA/mGluR via PSD and PI3K, or maintaining dopaminergic homeostasis via DARPP-32 phosphorylation and Akt/GSK3 signalling. DA signaling might further regulate CDK5 expression via ΔFosB. Deregulation of these pathways by CDK5 may alter synaptic transmission that may further lead to epileptogenesis.

D1R, dopamine receptor D1; D2R, dopamine receptor D2; TH, tyrosine 3-monooxygenase; cAMP, cyclic adenosine 3′,5′-monophosphate; PKA, cAMP-dependent protein kinase; pT34 and pT75, phospho threonine 34 and 75; DARPP-32, dopamine- and cAMP-regulated neuronal phosphoprotein; FosB, fosB proto-oncogene, AP-1, transcription factor subunit; GSK3β, glycogen synthase kinase-3 beta; SNARE, soluble N-ethylmaleimide-sensitive factor attachment protein receptor; PI3K, phosphatidylinositol 3-kinase; Akt, serine/threonine kinase; ErbB, epidermal growth factor receptor; NMDAR, glutamate receptor ionotropic, -methyl D-aspartate; AMPAR, 2-Amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid glutamate receptor; mGluR, metabotropic glutamate receptor; PSD, post synaptic density; PIK2, phosphatidylinositol 3-kinase 2.

GSK3β and related signalling pathways are implicated in the pathophysiology of various neurological as well as psychiatric disorders.

Role of CDK5 in epileptogenesis

Epileptogenesis is the process of generation of chronic spontaneous seizures driven by neuronal insults. The process of epileptogenesis includes multiple events related to cell death, cell survival and functions related to synaptic plasticity including neuronal death, neuronal migration, axonal sprouting, synaptic reorganization and gliosis. Therefore, there are many possibilities of abnormalities in different signalling mechanisms that could be responsible for the development of epilepsy. Here, we have mainly discussed the possible role of CDK5-mediated abnormal synaptic transmission in epileptogenesis. CDK5 is a versatile kinase with multiple neuronal functions.

There are several ways through which CDK5 can lead to epileptogenesis by modulating synaptic transmission. This section summarizes how deregulation of CDK5 can lead to epileptogenesis and also discusses the potential of CDK5 as a therapeutic target. CDK5 is a key player in regulating homeostatic plasticity which is crucial for stabilizing the activity of neurons and the neuronal circuits. Homoeostatic plasticity may play a role in the prevention of epilepsy by balancing the excitatory and inhibitory neurotransmission. Glutamatergic activation of ionotropic receptors mediated excitability is regulated by DA and metabotropic glutamate receptors (Fig. 3). Deregulated CDK5 may alter dopaminergic homeostasis in conditions of increased levels of glutamate causing excitotoxic damage. Glutamatergic activation of NMDAR and AMPAR causes increase in intracellular Ca²⁺ concentration, leading to increased CDK5 activity which in turn results in aberrations in neuronal excitability. There are reports showing such aberrant excitatory feedback circuit and spontaneous seizure in p352/2 mice, reflecting that CDK5 may also contribute to seizure activity. In normal conditions, CDK5 may inhibit abnormal epileptiform activity whereas induce it under conditions of stress or brain insults that result in non-physiological Ca²⁺ influx (Fig. 4).

CDK5 has been implicated in modulating long-term potentiation (LTP) and long-term depression (LTD). LTP and LTD are long-lasting alterations in the synaptic strength facilitated by modulations in synaptic activity.
Usually, high-frequency stimulations lead to LTP which facilitates synaptic efficacy for longer durations. On the other hand, low-frequency stimulation-induced LTD facilitates decrease in synaptic efficacy lasting for hours to months. In patients with temporal lobe epilepsy, a marked reduction of LTP was observed in the epileptic focus of hippocampus. One study has reported the role of CDK5 inhibition in LTP induction, and the proposed mechanisms include activation of DA and NMDAR, L-type Ca$^{2+}$ channels, PKA signalling and neurotransmitter release. Activation of NR2B and NR2A subunits containing NMDARs is shown to be associated with LTD and LTP, respectively. CDK5 can modulate both LTP and LTD by regulating various subunits of NMDARs. It inhibits clustering of NMDAR (calpain-mediated degradation of the NR2B NMDAR) and AMPAR (D-catenin-dependent localization of GluR2), resulting in excitability. In rat CA1 hippocampal neurons, CDK5 was shown to enhance NMDA-mediated currents by phosphorylation of the NR2A subunits. Therefore, CDK5 inhibition can block both inductions of LTP as well as NMDA-evoked currents.

**Cyclin-dependent kinase 5 (CDK5) as a potential prognostic/diagnostic biomarker**

A biomarker is defined as highly sensitive, specific and easily measurable molecular alterations of a normal or pathologic condition in a biological media such as human tissues, cells or fluids. Epilepsy is multifactorial and different epilepsy syndromes are associated with different pathophysologies. Therefore, it is not possible to have a single common set of biomarkers for all epilepsies; however, there is a possibility of limited commonalities for all of the DREs. Molecules associated with epileptogenesis and ictogenesis have potential to serve as biomarkers. These biomarkers can predict the development as well as the progression of an epileptic condition. These could also identify the epileptogenic focus by measuring the presence and severity of tissue capable of generating spontaneous seizures. These biomarkers can also be used to develop animal models for cost-effective screening of potential anti-epileptogenic and anti-seizure drugs and devices. The present epileptic biomarkers include imaging and electrophysiological measurements. We still do not have any definitive molecular or cellular biomarker for epilepsy, and till now, there are no biomarkers for DRE. The molecular mechanisms underlying DRE that differentiate it from other forms of epilepsy are still not clear and this could be contributing in part for the lack of biomarkers for DRE. The proposed mechanisms for DRE include inappropriate drug target as there are numerous receptors and ion channels with multiple isoforms involved in neuronal excitability, poor drug distribution due to overexpression of multidrug efflux genes and finally the homeostatic mechanisms that lead to the development of tolerance.

Deregulated CDK5 may lead to disrupted synaptic drive by modulating either LTP or LTD and may serve as a novel biomarker as well as a pharmacological target for treatment of epilepsy. It has been shown that long-term, but not acute loss of CDK5 activity can lead to increased Mg$^{2+}$-sensitive potentials. This will further lower the threshold for epileptiform activity and seizures. Thus, CDK5 is proposed to be activated as a homeostatic mechanism to attenuate epileptiform activity. Owing to the numerous neuronal functions, crosstalk with multiple intracellular signalling pathways, regulation of homeostatic plasticity and capability to increase the threshold for seizures CDK5 may play a crucial role in generating epileptiform activity and seizures and thus may serve as potential biomarkers of epileptogenesis and ictogenesis.

Although expression level analysis reveals modulation of CDK5 signalling in epilepsy, further validation studies for the role of this candidate gene or its interacting partners in epilepsy are so far conducted only in animal models of epilepsy. As none of the animal models for epilepsy could replicate the etiopathological conditions in humans, it is important to do such studies in human brain tissues to conceptualize its role in epileptogenesis in human. Gene expression analysis in resected brain tissues from...
human shows alterations in the mRNA levels of CDK5, and studies in animal models show modulations in the phosphorylated CDK5 (p-CDK5) levels\textsuperscript{11,18}.

Currently, anticonvulsant therapeutics is used to target either voltage-gated Na\textsuperscript{+} channels or T-type Ca\textsuperscript{2+} channels. These drugs are effective in only 70 per cent of adults suffering from recurrent seizures and are also associated with undesired side effects. In rat hippocampus, inhibition of CDK5 using a small molecule inhibitor resulted in significant increase in synaptic transmission\textsuperscript{13}. Another study proposed that the inhibitor targeted calcium channels as the small molecule inhibitor potentiated calcium currents even in the absence of p35, a major regulator for CDK5 in the brain\textsuperscript{94}. However, it has also been suggested that the residual activity could also be driven by p39, another regulator of CDK5\textsuperscript{30}. Numerous CDK5 inhibitors have been shown to be neuroprotective in both neuronal cell cultures and animal models. Roscovitine was shown to suppress ischaemia-induced tau hyperphosphorylation in animal stroke models\textsuperscript{95}. Olomoucine, another molecule with similar structure significantly reduced ischaemia-induced reactive astrogliosis\textsuperscript{96}. An inhibitory peptide which specifically targets the deregulated CDK5/p25 complex\textsuperscript{97}, was shown to provide neuroprotective effects in nerve cell cultures again supporting the notion that CDK5 could be a potential drug target in various neurological disorders.

Conclusions

CDK5 has significant implications in regulating synaptic plasticity, and as alterations of synaptic plasticity lead to epileptogenesis, it is proposed that deregulated CDK5-mediated altered synaptic transmission may lead to epileptogenesis. Targeting CDK5 and the downstream pathways might prove beneficial for the treatment of neurodegeneration and hyperexcitability observed in epilepsy. In addition, being a key regulator of homoeostatic plasticity, CDK5 may play a crucial role in the pathophysiology of DRE and may also have the potential to serve as a prognostic/diagnostic biomarker of DRE.

Conflicts of Interest: None.

References

1. Berg AT. Identification of pharmacoresistant epilepsy. Neurol Clin 2009; 27 : 1003-13.
2. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51 : 1069-77.
3. Chandra PS, Tripathi M. Epilepsy surgery: Recommendations for India. Ann Indian Acad Neurol 2010; 13 : 87-93.
4. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med 2011; 365 : 919-26.
5. Dixit AB, Banerjee J, Srivastava A, Tripathi M, Sarkar C, Kakkar A, et al. RNA-seq analysis of hippocampal tissues reveals novel candidate genes for drug refractory epilepsy in patients with MTLE-HS. Genomics 2016; 107 : 178-88.
6. Zhi QX, Fei X, Jie Y, Xue FW, Liang W, Feng YQ, et al. Gene expression analysis on anterior temporal neocortex of patients with intractable epilepsy. Synapse 2009; 63 : 1017-28.
7. Baraban SC, Tallent MK. Interneuron diversity series: Interneuronal neuropeptides – Endogenous regulators of neuronal excitation. Trends Neurosci 2004; 27 : 135-42.
8. Tallent MK, Qiu C. Somatostatin: An endogenous antiepileptic. Mol Cell Endocrinol 2008; 286 : 96-103.
9. Kwok-On L, Nancy NI. Recent advances in understanding the roles of CDK5 in synaptic plasticity. Biochim Biophys Acta 2009; 1792 : 741-5.
10. Cheung ZH, Fu AK, Nancy NIP. Synaptic roles of Cdk5: Implications in higher cognitive functions and neurodegenerative diseases. Neuron 2006; 50 : 13-8.
11. Mirza N, Vasiieva O, Marson AG, Pirmohamed M. Exploring the genomic basis of pharmacoresistance in epilepsy: An integrative analysis of large-scale gene expression profiling studies on brain tissue from epilepsy surgery. Hum Mol Genet 2011; 20 : 4381-94.
12. Cai XH, Tomizawa K, Tang D, Lu YF, Moriwaki A, Tokuda M, et al. Changes in the expression of novel Cdk5 activator messenger RNA (p39nck5ai mRNA) during rat brain development. Neurosci Res 1997 ; 28 : 355-60.
13. Lew J, Beaudette K, Litwin CM, Wang JH. Purification and characterization of a novel proline-directed protein kinase from bovine brain. J Biol Chem 1992; 267 : 13383-90.
14. Lopes JP, Agostinho P. Cdk5: Multitasking between physiological and pathological conditions. Prog Neurobiol 2011 ; 94 : 49-63.
15. Asada A, Yamamoto N, Gohda M, Saito T, Hayashi N, Hisanaga S. Myristoylation of p39 and p35 is a determinant of cytoplasmic or nuclear localization of active cyclin-dependent kinase 5 complexes. J Neurochem 2008; 106 : 1325-36.
16. Patzke H, Tsai LH. Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29. J Biol Chem 2002; 277 : 8054-60.
17. Ko J, Humbert S, Bronson RT, Takahashi S, Kulkarni AB, Li E, et al. p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neurosci 2001; 21 : 6758-71.
18. Kesavapany S, Lau KF, McLoughlin DM, Brownlees J, Ackerley S, Leigh PN, et al. p35/cdk5 binds and phosphorylates
beta-catenin and regulates beta-catenin/presenilin-1 interaction. *Eur J Neurosci* 2001; 13: 241-7.

19. Keshvara L, Magdaleno S, Benhayon D, Curran T. Cyclin-dependent kinase 5 phosphorylates disabled 1 independently of Reelin signaling. *J Neurosci* 2002; 22: 4869-77.

20. Singh KK, Ge X, Yao M, Drane L, Meletis K, Samuels BA, *et al.* Didx1 is a critical regulator of DISC1 and embryonic cortical development. *Neuron* 2010; 67: 33-48.

21. Ishizuka K, Kamiya A, Oh EC, Kanki H, Seshadri S, Robinson JF, *et al.* DISC1-dependent switch from progenitor proliferation to migration in the developing cortex. *Nature* 2011; 473: 92-6.

22. Tanaka T, Serno FF, Tseng HC, Kulkarni AB, Tsai LH, Gleeson JG. Cdk5 phosphorylation of doublecortin ser297 regulates its effect on neuronal migration. *Neuron* 2004; 41: 215-27.

23. Xie Z, Sanada K, Samuels BA, Shih H, Tsai LH. Serine 732 phosphorylation of FAK by Cdk5 is important for microtubule organization, nuclear movement, and neuronal migration. *Cell* 2003; 114: 469-82.

24. Nietherammer M, Smith DS, Ayala R, Peng J, Ko J, Lee MS, *et al.* NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein. *Neuron* 2000; 28: 697-711.

25. Kawauchi T, Chihama K, Nabeshima Y, Hoshino M. Cdk5 phosphorylates and stabilizes p27kip1 contributing to actin organization and cortical neuronal migration. *Nat Cell Biol* 2006; 8: 17-26.

26. Zuberker LR, Patrick GN, Nikolic M, Humbert S, Wu CL, Lanier LM, *et al.* Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. *Neuron* 2000; 26: 633-46.

27. Brown M, Jacobs T, Eickholt B, Ferrari G, Teo M, Monfries C, *et al.* Alpha2-chimaerin, cyclin-dependent Kinase 5/p35, and its target collapsin response mediator protein-2 are essential components in semaphorin 3A-induced growth-cone collapse. *J Neurosci* 2004; 24: 8994-9004.

28. Kato G, Maeda S. Neuron-specific Cdk5 kinase is responsible for mitosin-independent phosphorylation of c-Src at Ser75 in human Y79 retinoblastoma cells. *J Biochem* 1999; 126: 957-61.

29. Paglini G, Pigino G, Kunda P, Morfini G, Maccioni R, Quiroga S, *et al.* Evidence for the participation of the neuron-specific CDK5 activator P35 during laminin-enhanced axonal growth. *J Neurosci* 1998; 18: 9858-69.

30. Humbert S, Lanier LM, Tsai LH. Synaptic localization of p39, a neuronal activator of cdk5. *Neuroreport* 2000; 11: 2213-6.

31. Nikolic M, Chou MM, Lu W, Mayer BJ, Tsai LH. The p35/Cdk5 kinase is a neuron-specific Raf effector that inhibits Pak1 activity. *Nature* 1998; 395: 194-8.

32. Kesavapany S, Amin N, Zheng YL, Nijhara R, Jaffe H, Siag R, *et al.* p35/cyclin-dependent kinase 5 phosphorylation of ras guanine nucleotide releasing factor 2 (RasGRF2) mediates Ras-dependent Extracellular Signal-regulated kinase 1/2 activity, altering RasGRF2 and microtubule-associated protein 1b distribution in neurons. *J Neurosci* 2004; 24: 4421-31.

33. Cheung ZH, Chin WH, Chen Y, Ng YP, Ip NY. Cdk5 is involved in BDNF-stimulated dendritic growth in hippocampal neurons. *PLoS Biol* 2007; 5: e63.

34. Liang S, Wei FY, Wu YM, Tanabe K, Abe T, Oda Y, *et al.* Major Cdk5-dependent phosphorylation sites of amphiphysin 1 are implicated in the regulation of the membrane binding and endocytosis. *J Neurochem* 2007; 102: 1466-76.

35. Tomizawa K, Sunada S, Lu YF, Oda Y, Kinuta M, Ohshima T, *et al.* Cophosphorylation of amphiphysin I and dynamin I by Cdk5 regulates clathrin-mediated endocytosis of synaptic vesicles. *J Cell Biol* 2003; 163: 813-24.

36. Fletcher AI, Shuang R, Giovannucci DR, Zhang L, Bittner MA, Stuenkel EL. Regulation of c-Jun activity by cyclin-dependent kinase 5 via phosphorylation of Munc18. *J Biol Chem* 1999; 274: 4027-35.

37. Cheng K, Li Z, Fu WY, Wang JH, Fu AK, Ip NY. Petaire1 interacts with p35 and is a novel substrate for Cdk5/p35. *J Biol Chem* 2002; 277: 31988-93.

38. Taniguchi M, Taoka M, Itakura T, Saito T, Kinoshita M, *et al.* Phosphorylation of adult type Sept5 (CDCre1-1) by cyclin-dependent kinase 5 inhibits interaction with syntaxin-1. *J Biol Chem* 2007; 282: 7869-76.

39. Matsubara M, Kusubata M, Ishiguro K, Uchida T, Tanai K, Taniguchi H. Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions. *J Biol Chem* 1996; 271: 21108-13.

40. Lee SY, Wenk MR, Kim Y, Nairm AC, De Camilli P. Regulation of synaptotagmin 1 by cyclin-dependent kinase 5 at synapses. *Proc Natl Acad Sci U S A* 2004; 101: 546-51.

41. Samuels BA, Hsueh PY, Shu T, Liang H, Tseng HC, Hong CJ, *et al.* Cdk5 promotes synaptogenesis by regulating the subcellular distribution of the MAGUK family member CASK. *Neuron* 2007; 56: 823-37.

42. Wei FY, Nagashima K, Ohshima T, Saheki Y, Lu YF, Matsushita M, *et al.* Cdk5-dependent regulation of glucose-stimulated insulin secretion. *Nat Med* 2005; 11: 1104-8.

43. Tomizawa K, Ohta J, Matsushita M, Moriwaki A, Li ST, *et al.* Cdk5-dependent phosphorylation of doublecortin ser297 inhibits interaction with CDCrel-1 by cyclin-dependent kinase 5 inhibits interaction with syntaxin-1. *J Biol Chem* 2007; 282: 7869-76.

44. Poore CP, Sundaram JR, Pareek TK, Fu A, Amin N, Mohamed NE, *et al.* Cdk5-dependent phosphorylation of Delta-catenin regulates its localization and GluR2-mediated synaptic activity. *J Neurosci* 2010; 30: 8457-67.

45. Xin X, Wang Y, Ma XM, Rompolas P, Keutmann HT, Mains RE, *et al.* Regulation of Kalirin by Cdk5. *J Neurosci* 2008; 28(2 Pt 15): 2601-11.

46. Wang J, Liu S, Fu Y, Wang JH, Lu Y. Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. *Nat Neurosci* 2003; 6: 1039-47.
Regulation of protein
Acute or chronic stress
2001;

Anti-diabetic drugs inhibit obesity-linked
2007;

61. Tian B, Yang Q, Mao Z. Phosphorylation of ATM by Cdk5 mediates DNA damage signalling and regulates neuronal death. Nat Cell Biol 2009; 11 : 211-8.

62. Schubert S, Knoch KP, Ouwendijk J, Mohammed S, Bodrov Y, Jäger M, et al. B2-syntrophin is a Cdk5 substrate that restrains the motility of insulin secretory granules. PLoS One 2010; 5 : e12929.

63. Cheung ZH, Gong K, Ip NY. Cdk5-dependent kinase 5 supports neuronal survival through phosphorylation of Bcl-2. J Neurosci 2008; 28 : 4872-7.

64. Maestre C, Delgado-Esteban M, Gomez-Sanchez JC, Bolaños JP, Almeida A. Cdk5 phosphorylates Cdh1 and modulates cyclin B1 stability in excitotoxicity. EMBO J 2008; 27 : 2736-45.

65. Fu AK, Fu WY, Cheung J, Tsim KW, Ip FC, Wang JH, et al. Cdk5 is involved in neuregulin-induced AChR expression at the neuromuscular junction. Nat Neurosci 2001; 4 : 374-81.

66. Adzic M, Djordjevic J, Djordjevic A, Niciforovic A, Demonacos C, Radojicic M, et al. Acute or chronic stress induce cell compartment-specific phosphorylation of glucocorticoid receptor and alter its transcriptional activity in Wistar rat brain. J Endocrinol 2009; 202 : 87-97.

67. Li BS, Zhang L, Takahashi S, Ma W, Jaffe H, Kulkarni AB, et al. Cyclin-dependent kinase 5 prevents neuronal apoptosis by negative regulation of e-Jun N-terminal kinase 3. EMBO J 2002; 21 : 324-33.

68. Sharma P, Veeranna, Sharma M, Amin ND, Siah RK, Grant P, et al. Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway. J Biol Chem 2002; 277 : 528-34.

69. Li Z, David G, Hung KW, DePinho RA, Fu AK, Ip NY. Cdk5/p35 phosphorylates mSds3 and regulates mSds3-mediated repression of transcription. J Biol Chem 2004; 279 : 54438-44.

70. Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J Biol Chem 1998; 273 : 4257-64.

71. Zhang J, Krishnamurthy PK, Johnson GV. Cdk5 phosphorylates p53 and regulates its activity. J Neurochem 2002; 81 : 307-13.

72. Miyamoto Y, Yamauchi J, Chan JR, Okada A, Tomooka Y, Hisanaga S, et al. Cdk5 regulates differentiation of oligodendrocyte precursor cells through the direct phosphorylation of paxillin. J Cell Sci 2007; 120 (Pt 24) : 4355-66.

73. Lee SY, Voronov S, Letinich K, Nairn AC, Di Paolo G, De Camilli P. Regulation of the interaction between PIPKI gamma and talin by proline-directed protein kinases. J Cell Biol 2005; 168 : 789-99.

74. Choi IH, Banks AS, Estall JL, Kajimura S, Boström P, Laznik D, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010; 466 : 451-6.

75. Kim SH, Ryan TA. CDK5 serves as a major control point in neurotransmitter release. Neuron 2010; 67 : 797-809.

76. Noble W, Olm V, Takata K, Casey E, Maryson J, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003; 38 : 555-65.
77. Paoletti P., Vila I., Rifé M., Lizcano JM., Alberch J., Ginés S. Dopaminergic and glutamatergic signaling crosstalk in Huntington’s disease neurodegeneration: The role of p25/cyclin-dependent kinase 5. J Neurosci 2008; 28 : 10090-101.

78. Shuang R., Zhang L., Fletcher A., Groblewski GE., Pevssner J., Stuenkel EL. Regulation of Munc-18/syntaxin 1A interaction by cyclin-dependent kinase 5 in nerve endings. J Biol Chem 1998; 273 : 4957-66.

79. Samuels BA., Tsai LH. Cdk5 is a dynamo at the synapse. Nat Cell Biol 2003; 5 : 689-90.

80. Chergui K., Svenningsson P., Greengard P. Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum. Proc Natl Acad Sci U S A 2004; 101 : 2191-6.

81. Putkonen N., Kukkonen JP., Mudo G., Putula J., Belluardo N., Lindholm D., et al. Involvement of cyclin-dependent kinase-5 in the kainic acid-mediated degeneration of glutamatergic synapses in the rat hippocampus. Eur J Neurosci 2011; 34 : 1212-21.

82. Pak DT., Sheng M. Targeted protein degradation and synapse remodeling by an inducible protein kinase. Science 2003; 302 : 1368-73.

83. Hawkins AH., Koovakkattu D., Hayashi K., Anderson AE., Powell CM., Sinton CM., et al. Regulation of hippocampal and behavioral excitability by cyclin-dependent kinase 5. PLoS One 2009; 4 : e5808.

84. Chen P., Gu Z., Liu W., Yan Z. Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons. Mol Pharmacol 2007; 72 : 40-51.

85. Jeong J., Park YU., Kim DK., Lee S., Kwak Y., Lee SA., et al. Cdk5 phosphorylates dopamine D2 receptor and attenuates downstream signaling. PLoS One 2013; 8 : e84482.

86. Chen J., Zhang Y., Kelz MB., Steffen C., Ang ES., Zeng L., et al. Induction of cyclin-dependent kinase 5 in the hippocampus by chronic electroconvulsive seizures: Role of [Delta]FosB. J Neurosci 2000; 20 : 8965-71.

87. Bozzi Y., Borrelli E. The role of dopamine signaling in epileptogenesis. Front Cell Neurosci 2013; 7 : 157.

88. Bliss TVP., Cooke SM. Long-term potentiation and long-term depression: A clinical perspective. Clinics (Sao Paulo) 2011; 66 (Suppl 1) : 3-17.

89. Beck H., Goussakov IV., Lie A., Helmstaedter C., Elger CE. Synaptic plasticity in the human dentate gyrus. J Neurosci 2000; 20 : 7080-6.

90. Miranda-Barrientos J., Nieto-Mendoza E., Hernández-Echeagaray E. The Cdk5 inhibitor Roscovitine increases LTP induction in corticostralial synapses. ASN Neuro 2014; 6. pii: e00140.

91. Li BS., Sun MK., Zhang L., Takahashi S., Ma W., Vinade L., et al. Regulation of NMDA receptors by cyclin-dependent kinase-5. Proc Natl Acad Sci U S A 2001; 98 : 12742-7.

92. Naylor S. Biomarkers: Current perspectives and future prospects. Expert Rev Mol Diagn 2003; 3 : 525-9.

93. Engel J Jr., Pitkänen A., Loeb JA., Dudek FE., Bertram EH 3rd., Cole AJ., et al. Epilepsy biomarkers. Epilepsia 2013; 54 (Suppl 4) : 61-9.

94. Yan Z., Chi P., Bibb JA., Ryan TA., Greengard P. Roscovitine: A novel regulator of P/Q-type calcium channels and transmitter release in central neurons. J Physiol 2002; 540 (Pt 3) : 761-70.

95. Menn B., Bach S., Blevins TL., Campbell M., Meijer L., Timsit S. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One 2010; 5 : e12117.

96. Zhu Z., Zhang Q., Yu Z., Zhang L., Tian D., Zhu S., et al. Inhibiting cell cycle progression reduces reactive astrogliosis initiated by scratch injury in vitro and by cerebral ischemia in vivo. Glia 2007; 55 : 546-58.

97. Kanungo J., Zheng YL., Amin ND., Pant HC. Targeting Cdk5 activity in neuronal degeneration and regeneration. Cell Mol Neurobiol 2009; 29 : 1073-80.

Reprint requests: Dr Aparna Banerjee Dixit, Center for Excellence in Epilepsy, A Joint NBRC-AIIMS Collaboration, National Brain Research Centre, Gurugram 122 051, Haryana, India
e-mail: aparnabanerjeedixit@gmail.com